GUCA1A-Related Retinopathy: Disease Characteristics Research Report

Executive summary

GUCA1A-related retinopathy (MONDO:0700376) is a rare, nonsyndromic, usually autosomal-dominant inherited retinal disease caused by heterozygous missense variants in GUCA1A, which encodes guanylate cyclase-activating protein 1 (GCAP1). It forms a phenotypic continuum encompassing macular dystrophy, cone dystrophy, cone–rod dystrophy and, rarely, an RP-like generalized degeneration. The core manifestations are progressive, bilateral central visual loss, impaired color discrimination and photophobia, with outer-retinal/macular atrophy and cone-predominant electroretinographic dysfunction. The best quantitative disease-specific natural-history evidence is a 2025 retrospective cohort of 19 patients from 14 families; no comparably comprehensive 2023–2024 clinical cohort was retrieved. (OpenTargets Search: GUCA1A-related retinopathy-GUCA1A, allon2025clinicalgeneticimaging pages 1-2, allon2025clinicalgeneticimaging pages 4-5)

The principal mechanism is not simple haploinsufficiency. Most pathogenic GCAP1 variants impair Ca²⁺ sensing and permit inappropriate activation of retinal guanylate cyclase at Ca²⁺ concentrations that should inhibit it, disturbing cGMP/Ca²⁺ homeostasis and ultimately injuring photoreceptors. There is currently no approved GUCA1A-specific disease-modifying treatment or relevant human interventional trial in the retrieved evidence. AAV-delivered RNA interference has delayed degeneration and improved function in mutant-GCAP1 mice, but remains preclinical. (marino2018anovelp.(glu111val) pages 3-3, kitiratschky2009mutationsinthe pages 1-3, dell’orco2019normalgcapspartly pages 1-2, jiang2013rnaimediatedgenesuppression pages 13-13)

The following compact table is suitable for initial knowledge-base ingestion.

Table: Compact evidence table covering disease identity, genetics, phenotype, mechanism, diagnostic approach, prognosis, treatment status, experimental models and major knowledge gaps. Ontology mappings are explicitly suggested rather than asserted.

1. Disease information

Definition and scope

GUCA1A-related retinopathy is a Mendelian photoreceptor degeneration in which cone dysfunction usually dominates. Clinical labels historically assigned to affected families include:

• GUCA1A-associated/related retinopathy or retinal dystrophy;
• GCAP1-related retinopathy;
• autosomal-dominant cone dystrophy, historically cone dystrophy 3/COD3;
• autosomal-dominant cone–rod dystrophy;
• GUCA1A-related macular dystrophy or maculopathy;
• central areolar choroidal dystrophy-like maculopathy;
• rarely, an RP-like phenotype. (allon2025clinicalgeneticimaging pages 1-2, chen2017guca1amutationcauses pages 7-8, georgiou2020retinalimagingin pages 13-15)

The foundational 1998 report identified p.Tyr99Cys in an autosomal-dominant cone-dystrophy pedigree. A later clinical series established that GUCA1A variants can cause “cone, cone-rod, and macular dystrophy” (Michaelides et al., Ophthalmology, August 2005; PMID 15953638). (payne1998amutationin pages 3-3, georgiou2020retinalimagingin pages 13-15)

Identifiers

• MONDO: MONDO:0700376, GUCA1A-related retinopathy; Open Targets maps this entity principally to GUCA1A/ENSG00000048545. (OpenTargets Search: GUCA1A-related retinopathy-GUCA1A)
• Gene: GUCA1A; approved name guanylate cyclase activator 1A.
• A disease-specific ICD-10, ICD-11 or MeSH code was not established in the retrieved sources; implementation should use a broader inherited retinal/cone–rod dystrophy code plus the molecular diagnosis.
• OMIM/Orphanet identifiers should be verified directly against those live resources before database ingestion; the retrieved primary texts did not provide a sufficiently reliable disease-level identifier.

This report synthesizes aggregated disease-level literature and retrospective cohorts, not individual EHR records. The 2025 study used molecularly confirmed clinical records from a specialist referral center. (allon2025clinicalgeneticimaging pages 4-5, allon2025clinicalgeneticimaging pages 1-2)

2. Etiology, risk and protective factors

Causal factor

The primary cause is a heterozygous germline GUCA1A missense variant, generally producing altered-function GCAP1. Familial segregation and multigenerational transmission support autosomal-dominant causality. All 19 patients in the largest cohort carried pathogenic or likely pathogenic heterozygous missense alleles. (allon2025clinicalgeneticimaging pages 5-10, marino2018anovelp.(glu111val) pages 8-9, kitiratschky2009mutationsinthe pages 1-3)

Genetic risk factors

Disease risk is dominated by carrying a pathogenic allele. Variants frequently affect or perturb the EF-hand Ca²⁺-sensing regions. Documented alleles include p.Tyr99Cys, p.Asp100Glu, p.Asn104His, p.Ile107Thr, p.Glu111Ala/Val, p.Arg120Leu, p.Leu151Phe, p.Glu155Gly, p.Gly159Val, p.Leu176Phe, p.Leu84Phe and p.Glu89Lys. The 2025 cohort contained five alleles: p.Tyr99Cys in 10 of 14 families, with p.Leu84Phe, p.Ile107Thr, p.Glu111Ala and p.Leu176Phe in one family each. (allon2025clinicalgeneticimaging pages 1-2, allon2025clinicalgeneticimaging pages 2-4, marino2018anovelp.(glu111val) pages 3-3, kitiratschky2009mutationsinthe pages 1-3, chen2017guca1amutationcauses pages 7-8)

Family history is therefore a major risk indicator, but apparently sporadic cases may represent de novo variants or unrecognized reduced penetrance. Penetrance is not robustly quantified. Marked inter- and intrafamilial variability is documented; p.Arg120Leu produced maculopathy ranging from mild photoreceptor degeneration to severe central areolar choroidal dystrophy in one five-generation family. (allon2025clinicalgeneticimaging pages 10-10, chen2017guca1amutationcauses pages 7-8, georgiou2020retinalimagingin pages 13-15)

Modifiers and protective factors

No validated human modifier gene or protective allele has been established. Wild-type GCAP1 partly attenuated E111V-induced cyclase dysregulation in biochemical experiments. Mouse modeling suggested GCAP2 may add compensation, but human GCAP2 did not activate GC1 over the tested physiological Ca²⁺ range; this is a proposed species-dependent compensatory mechanism, not a proven human modifier. (dell’orco2019normalgcapspartly pages 1-2)

No disease-specific protective diet, lifestyle intervention or medication is established. Environmental toxins, smoking, alcohol, occupation, infection, sex and age are not primary causes. A 2025 cohort found worse acuity in males, but this exploratory association requires replication. Age predicts accumulated severity rather than genetic susceptibility. (allon2025clinicalgeneticimaging pages 4-5, allon2025clinicalgeneticimaging pages 10-10)

Gene–environment interaction

No reproducible GUCA1A-specific gene–environment interaction was found. Ordinary light drives the pathway in which GCAP1 functions, but available evidence does not establish routine light exposure as a modifiable cause or prove that light avoidance changes progression.

3. Phenotypes

In the 2025 cohort, mean symptom onset was 23 years (range 5–74). Initial complaints were impaired color discrimination in 68.4%, central visual loss in 21.1%, photophobia in 5.3% and unremembered in 5.3%. Across follow-up, central visual deficits occurred in 89.5%, color deficits in 84.2% and photophobia in 78.9%; nyctalopia and metamorphopsia each occurred in 5.3%. (allon2025clinicalgeneticimaging pages 4-5, allon2025clinicalgeneticimaging pages 10-10)

These mappings are suggested labels; exact HPO identifiers should be resolved through the current HPO release. The phenotype is generally highly symmetric between eyes. Rod-specific ERGs are often normal, while severe E111V disease can reduce both cone and rod responses. (allon2025clinicalgeneticimaging pages 10-13, allon2025clinicalgeneticimaging pages 5-10, marino2018anovelp.(glu111val) pages 2-3)

No GUCA1A-specific EQ-5D, SF-36, PROMIS or validated vision-related quality-of-life dataset was found. Nevertheless, progressive loss of central acuity, color discrimination and light tolerance predict substantial effects on reading, facial recognition, driving, education and employment; these functional consequences are clinical inference rather than quantified disease-specific outcomes.

4. Genetic and molecular information

Gene and variant classes

GUCA1A encodes GCAP1, a neuronal calcium-sensor expressed in rods and cones, with stronger cone immunoreactivity. The disease-associated variants in the retrieved human series were overwhelmingly germline, heterozygous missense variants. No recurrent pathogenic copy-number alteration, aneuploidy, translocation, repeat expansion, mitochondrial mutation or somatic mechanism was established. (kitiratschky2009mutationsinthe pages 1-3, payne1998amutationin pages 3-3)

Representative HGVS alleles include:

• NM_000409:c.332A>T, p.Glu111Val—absent from public databases available to its discoverers; failed to inhibit cyclase adequately at high Ca²⁺. (marino2018anovelp.(glu111val) pages 3-3)
• c.265G>A, p.Glu89Lys; c.300T>A, p.Asp100Glu; c.476G>T, p.Gly159Val; and c.451C>T, p.Leu151Phe—all altered Ca²⁺-dependent cyclase regulation. The novel alleles were absent from 200 control chromosomes, but precise modern gnomAD frequencies were not supplied. (kitiratschky2009mutationsinthe pages 1-3)
• c.250C>T, p.Leu84Phe and c.320T>C, p.Ile107Thr—reported in autosomal-dominant retinal degeneration; functional mechanism was initially predicted rather than fully demonstrated. (allon2025clinicalgeneticimaging pages 2-4)
• p.Asn104His doubled the reported inhibitory midpoint from 260 nM for wild type to 520 nM and increased GC affinity, consistent with persistent activity at physiological Ca²⁺. This biochemical result was reported in 2021, not in a 2023–2024 human trial.

Variant classification must be performed allele by allele under current ACMG/AMP criteria. A missense change or rare population frequency alone is insufficient; segregation, phenotype match, functional data and independent observations are important. The 2025 cohort used ACMG classification and included only pathogenic/likely pathogenic alleles. (allon2025clinicalgeneticimaging pages 5-10, allon2025clinicalgeneticimaging pages 4-5)

Modifiers, epigenetics and structural variation

No validated modifier gene, disease-specific methylation signature, histone alteration or chromatin mechanism was identified. Likewise, no recurrent large chromosomal abnormality defines this disorder.

5. Environmental information

This is primarily a genetic photoreceptor disorder. No causal toxin, radiation exposure, pollutant, occupation, diet, smoking pattern, alcohol exposure or infectious agent is established. There is no zoonotic or transmissible component. Evidence is insufficient to claim that sunglasses, supplements or dietary manipulation alter the molecular course, although glare control may improve comfort symptomatically.

6. Mechanism and pathophysiology

Ordered causal chain

1. A heterozygous GUCA1A missense lesion leads to structurally altered GCAP1, commonly affecting Ca²⁺ coordination or conformational switching in EF-hand regions. (marino2018anovelp.(glu111val) pages 8-9, payne1998amutationin pages 3-3)
2. Altered GCAP1 leads to reduced Ca²⁺ sensitivity or stabilization of the Mg²⁺-bound activating conformation. (marino2018anovelp.(glu111val) pages 8-9, marino2018anovelp.(glu111val) pages 3-3)
3. This leads to failure to suppress retinal guanylate cyclase—principally GC1/RetGC1 encoded by GUCY2D—when intracellular Ca²⁺ is high, including dark-adapted conditions. (marino2018anovelp.(glu111val) pages 3-3, dell’orco2019normalgcapspartly pages 1-2)
4. Persistent cyclase activity leads to excessive or mistimed cGMP synthesis and impaired recovery/homeostasis of phototransduction. (kitiratschky2009mutationsinthe pages 1-3, dell’orco2019normalgcapspartly pages 1-2)
5. Excess cGMP leads to persistent opening/dysregulation of cGMP-gated channels and increased outer-segment Ca²⁺ load; the exact quantitative chain is demonstrated most strongly in biochemical and animal systems and inferred in human retina. (dell’orco2019normalgcapspartly pages 1-2)
6. Branch A: disturbed cGMP/Ca²⁺ homeostasis leads to early cone/rod response abnormalities and synaptic/network dysfunction. Branch B: chronic second-messenger toxicity leads to photoreceptor stress and death; downstream death effectors are not fully resolved for human GUCA1A disease. (jiang2013rnaimediatedgenesuppression pages 13-13, avesani2026retinalnetworkdysfunction pages 14-17, avesani2026retinalnetworkdysfunction pages 12-14)
7. Cone-predominant photoreceptor dysfunction and loss lead to color-vision impairment, photophobia, central scotoma and reduced central acuity; broader rod involvement leads to cone–rod or RP-like disease. (allon2025clinicalgeneticimaging pages 4-5, allon2025clinicalgeneticimaging pages 5-10, marino2018anovelp.(glu111val) pages 2-3)
8. Progressive outer-retinal and later RPE atrophy results in chronic, irreversible macular degeneration and severe visual disability. (allon2025clinicalgeneticimaging pages 10-13, chen2017guca1amutationcauses pages 7-8)

Normal pathway and protein dysfunction

In light, phototransduction lowers cytoplasmic cGMP, closes cyclic-nucleotide-gated channels, hyperpolarizes the photoreceptor and lowers intracellular Ca²⁺. Low-Ca²⁺/Mg²⁺-bound GCAP1 activates RetGC to replenish cGMP; at high dark-state Ca²⁺, Ca²⁺-bound GCAP1 suppresses cyclase. Disease variants uncouple this feedback. (kitiratschky2009mutationsinthe pages 1-3, payne1998amutationin pages 3-3)

The 2018 E111V study found no major secondary/tertiary structural rearrangement but did find stabilization/rigidification of the activating state and residual cyclase activation at high Ca²⁺. Its key conclusion, reflected directly in the title, was that the variant “leads to impaired calcium sensing and perturbed second messenger homeostasis in photoreceptors.” (marino2018anovelp.(glu111val) pages 8-9, marino2018anovelp.(glu111val) pages 3-3)

Cells, processes and ontology suggestions

• Cell types: cone photoreceptor cell; rod photoreceptor cell; retinal pigment epithelial cell. Suggested CL concepts should be matched to the current Cell Ontology.
• GO biological processes: visual phototransduction; phototransduction recovery; detection of light stimulus; calcium-ion sensing; regulation of guanylate cyclase activity; cGMP biosynthetic process; calcium-ion homeostasis; photoreceptor-cell maintenance; photoreceptor-cell death.
• GO cellular components: photoreceptor outer segment; photoreceptor inner segment; plasma membrane; cytosol.

Inflammation is not established as an initiating human mechanism. Early mitochondrial, synaptic and inflammatory alterations were reported only in a 2026 E111V mouse preprint and should be treated as emerging model evidence, not settled human pathophysiology. (avesani2026retinalnetworkdysfunction pages 14-17)

Molecular profiling and advanced technologies

No disease-specific human single-cell, spatial-transcriptomic, proteomic, metabolomic, lipidomic or epigenomic signature was identified. Biophysical assays, molecular-dynamics simulations and engineered animal studies currently provide more mechanistic resolution than human omics. (marino2018anovelp.(glu111val) pages 8-9, marino2018anovelp.(glu111val) pages 3-3)

7. Anatomical structures affected

• Organ/system: eye; retina within the visual nervous system. No consistent extraocular syndrome is established.
• Primary site: bilateral neural retina, especially central macula and cone-rich outer retina.
• Cells: cone photoreceptors first or most severely; rods variably; RPE becomes involved in advanced maculopathy and in zebrafish models.
• Subcellular site: GCAP1-mediated signaling at photoreceptor outer-segment membranes in association with retinal guanylate cyclase; OCT abnormalities localize initially to the ellipsoid/outer-photoreceptor zone.
• Suggested UBERON concepts: eye, retina, neural retina, macula, retinal pigment epithelium, photoreceptor outer segment.
• Lateralization: bilateral, generally highly symmetric; the 2025 interocular acuity correlation was 0.90. (allon2025clinicalgeneticimaging pages 1-2, allon2025clinicalgeneticimaging pages 10-13, chen2017guca1amutationcauses pages 7-8)

8. Temporal development

Onset is chronic and usually insidious, ranging from childhood to late adulthood. In the largest cohort, mean onset was 23 years and the range was 5–74. Severe E111V disease may present congenitally with nystagmus, photophobia and marked acuity loss. (allon2025clinicalgeneticimaging pages 4-5, marino2018anovelp.(glu111val) pages 2-3)

A practical staging framework is:

1. Early functional disease: color discrimination difficulty and photophobia; FAF may be abnormal before color fundus examination.
2. Early structural maculopathy: ellipsoid-zone irregularity or optical gap.
3. Established cone dystrophy: reduced photopic ERG, central/paracentral scotoma and progressive acuity loss.
4. Advanced macular/cone–rod disease: outer-retinal and outer-nuclear-layer atrophy, RPE atrophy and possible peripheral degeneration.
5. End-stage visual impairment: extensive photoreceptor loss and, in rare severe cases, light perception or no light perception. (allon2025clinicalgeneticimaging pages 10-13, allon2025clinicalgeneticimaging pages 5-10)

Visual acuity declined by approximately 0.20 logMAR per decade in the 2025 cohort, but progression is highly variable and some individuals retain relatively good vision beyond age 70. There is no established remission pattern; the disease is chronic and generally progressive. (allon2025clinicalgeneticimaging pages 4-5, allon2025clinicalgeneticimaging pages 10-10)

9. Inheritance and population

Inheritance is predominantly autosomal dominant. Thirteen of 14 families in the largest cohort had multiple-generation involvement. Each child of a heterozygous affected individual ordinarily has a 50% transmission probability, although clinical severity cannot be predicted reliably. (allon2025clinicalgeneticimaging pages 4-5)

Penetrance is not accurately quantified. Two apparently sporadic cases could not distinguish de novo variation from reduced penetrance. Expressivity is clearly variable, including within families. No genetic anticipation, recurrent germline mosaicism, consanguinity effect or established founder allele was identified. Because affected heterozygotes are not asymptomatic “carriers” in the recessive sense, carrier-frequency language is generally inappropriate; population pathogenic-allele frequency remains unknown. (allon2025clinicalgeneticimaging pages 10-10, chen2017guca1amutationcauses pages 7-8)

Disease-specific population prevalence and incidence are unavailable. GUCA1A accounted for approximately 0.1%–0.7% of IRD cohorts, 3% of one autosomal-dominant non-RP subgroup, and 1.2% of a German macular/cone-dystrophy cohort (1.6% among molecularly solved cases). These are referral-cohort proportions, not population prevalence. (allon2025clinicalgeneticimaging pages 2-4)

No reproducible ethnic, geographic or sex ratio has been established. The recent male-severity signal should not be interpreted as male-limited inheritance. (allon2025clinicalgeneticimaging pages 4-5)

10. Diagnostics

Clinical workflow

1. Record onset, progression, family history, photophobia, color impairment, central vision and nyctalopia.
2. Measure best-corrected visual acuity and perform slit-lamp/fundus examination.
3. Test color discrimination and central/peripheral visual fields.
4. Obtain macular spectral-domain OCT, short-wavelength fundus autofluorescence and widefield color/pseudocolor imaging.
5. Use ISCEV-standard pattern ERG to assess macular function and full-field ERG, including photopic on–off responses, to distinguish cone-predominant from cone–rod disease.
6. Confirm molecularly with an inherited-retinal-disease NGS panel, WES or WGS; validate/phase and assess segregation by Sanger sequencing when appropriate; classify under current ACMG/AMP standards. (allon2025clinicalgeneticimaging pages 4-5, marino2018anovelp.(glu111val) pages 2-3, allon2025clinicalgeneticimaging pages 2-4)

FAF may detect maculopathy before conventional fundus abnormalities but is not genotype-specific. OCT typically progresses from ellipsoid-zone irregularity/optical gap to outer-retinal, outer-nuclear-layer and RPE atrophy. PERG P50 is often undetectable with severe macular involvement. Full-field ERG distinguished cone dystrophy in 11/13 tested recent patients from macular dystrophy with normal full-field responses in 2/13. (allon2025clinicalgeneticimaging pages 10-13, allon2025clinicalgeneticimaging pages 5-10)

CMA, karyotyping, FISH, mtDNA analysis and repeat-expansion testing are not first-line for a classic dominant GUCA1A phenotype. They may be used only when the broader presentation suggests another diagnosis. RNA-seq and other omics are research tools, not validated diagnostics.

Differential diagnosis

The differential includes other inherited cone/cone–rod or macular dystrophies—especially GUCY2D, PRPH2, ABCA4, CRX, RPGR, PROM1, CDHR1, CNGA3/CNGB3—and acquired toxic, autoimmune or age-related maculopathy. Distinguishing clues are dominant transmission, cone-predominant ERG dysfunction, symmetric outer-retinal maculopathy and a pathogenic GUCA1A allele. Imaging alone is insufficient because FAF/OCT appearances overlap across genotypes. (allon2025clinicalgeneticimaging pages 10-13, georgiou2020retinalimagingin pages 13-15)

Screening

Population or newborn screening is not established. Cascade genetic testing is appropriate for adult relatives after the familial pathogenic variant is known. Predictive testing of minors requires genetics/ophthalmology counseling and consideration of whether results alter childhood surveillance or management.

11. Outcome and prognosis

GUCA1A retinopathy is not known to reduce life expectancy or cause disease-specific mortality. Morbidity is visual. In the 2025 cohort, mean right-eye acuity changed from 0.67 to 0.94 logMAR and left-eye acuity from 0.63 to 0.95 over a mean follow-up of approximately 10 years; the observed range extended from 0.00 logMAR to no light perception. (allon2025clinicalgeneticimaging pages 1-2, allon2025clinicalgeneticimaging pages 4-5)

Prognostic indicators include age, baseline macular structure/function and probably genotype. p.Leu84Phe was associated with earlier loss, p.Glu111Ala with worse vision, and p.Ile107Thr with later/milder disease, but each rare subgroup was very small. Extensive central atrophy and complete photoreceptor-layer loss correlate with worse acuity. (allon2025clinicalgeneticimaging pages 10-13, allon2025clinicalgeneticimaging pages 10-10)

Recovery of lost photoreceptors is not expected with current supportive care. A rare Coats-like reaction with exudative retinal detachment was reported, but this is not a typical complication. No validated circulating or molecular prognostic biomarker exists beyond genotype and retinal structural/functional measures. (allon2025clinicalgeneticimaging pages 4-5)

12. Treatment

Current clinical care

No GUCA1A-specific pharmacotherapy, gene therapy, RNA therapy, cell therapy or approved surgical treatment was identified. Present management is supportive:

• individualized refractive correction;
• tinted lenses/glare control for photophobia;
• low-vision assessment and optical/electronic aids;
• orientation, mobility, educational and occupational accommodations;
• monitoring by an inherited-retinal-disease service using acuity, OCT/FAF and functional testing;
• treatment of unrelated or secondary ocular complications according to standard practice;
• genetic counseling and access to IRD registries/natural-history research.

Suggested NCIT intervention concepts are Low Vision Rehabilitation, Assistive Device, Genetic Counseling, Gene Silencing Therapy, and Adeno-Associated Virus Vector Therapy; the latter two are experimental for this disease.

Preclinical advanced therapeutics

A non-allele-specific silencing strategy is mechanistically attractive because many variants are dominant gain-of-function alleles. In L151F mice, scAAV2/8-delivered shRNA suppressed mutant GCAP1 by about 70% and endogenous GCAP1 by about 90%. In a Y99C model, approximately 80% transgene silencing persisted for nearly one year and improved photoreceptor survival, delayed degeneration and improved visual function. Risks include suppression of normal GCAP1, RNAi saturation and off-target effects. (jiang2013rnaimediatedgenesuppression pages 13-13, jiang2013rnaimediatedgenesuppression pages 1-2)

The investigators characterized these results as a “proof of concept” for RNAi-based treatment of dominant GCAP1 disease. No human response rate or safety estimate exists. Gene supplementation alone is unlikely to neutralize a dominant toxic allele; silencing-and-replacement, allele-specific RNAi, antisense approaches or editing may ultimately be more appropriate. (jiang2012rnainterferencegene pages 158-159)

No relevant GUCA1A human interventional trial/NCT identifier was found. A search hit for “GCAP” referred to an unrelated bladder-cancer chemotherapy acronym and must not be included as a retinal trial.

13. Prevention

Primary lifestyle prevention is unavailable because the initiating cause is inherited. Secondary prevention consists of molecular diagnosis, surveillance and identifying relatives early enough for counseling, visual support and future trial eligibility. Tertiary prevention aims to limit disability through glare control, low-vision rehabilitation, workplace/school accommodation and treatment of secondary ocular complications.

Genetic counseling should explain autosomal-dominant transmission, variable expressivity and uncertain severity. Once a familial pathogenic variant is established, reproductive options may include prenatal diagnosis or preimplantation genetic testing, subject to local regulation and nondirective counseling. Vaccination, antimicrobial prophylaxis and public-health environmental measures are not applicable.

14. Other species and natural disease

No naturally occurring GUCA1A-equivalent veterinary disease was identified in companion animals, livestock or wildlife. There is no zoonotic potential or cross-species transmission. Orthologous Guca1a genes in mouse and zebrafish support strongly conserved calcium-dependent phototransduction, but the reported diseases are engineered experimental models rather than natural animal cases. Exact NCBI Gene and Taxon identifiers should be resolved directly from current NCBI records before ingestion.

15. Model organisms

Mouse models (Mus musculus)

• Y99C transgenic: rapid, expression-dose-dependent photoreceptor degeneration and a useful allele-specific RNAi model. (dell’orco2019normalgcapspartly pages 1-2, jiang2012rnainterferencegene pages 158-159)
• L151F genomic transgenic: late-onset, slowly progressive cone–rod degeneration resembling human GCAP1-CORD; photopic b-wave was approximately 60% of normal at 12 months. (jiang2013rnaimediatedgenesuppression pages 13-13, jiang2013rnaimediatedgenesuppression pages 1-2)
• E155G knock-in: normal early development followed by progressive cone-predominant dysfunction and photoreceptor loss; 12-month photopic b-wave was approximately 42% of normal. cGMP accumulation preceded structural degeneration, supporting its upstream pathogenic role. (jiang2013rnaimediatedgenesuppression pages 13-13)
• E111V knock-in: a 2026 non-peer-reviewed preprint reports functional/network abnormalities before major structural loss, with outer-nuclear-layer thinning only later. Acute ex-vivo wild-type GCAP1 partially corrected rod-response kinetics; this is proof of biochemical modifiability, not therapeutic efficacy. (avesani2026retinalnetworkdysfunction pages 14-17, avesani2026retinalnetworkdysfunction pages 12-14)

Mouse limitations include a rod-dominant retina, transgene dosage effects, retention of endogenous normal alleles in some lines and species-specific GCAP2 compensation. These differences can exaggerate or attenuate the human cone-predominant phenotype. (jiang2013rnaimediatedgenesuppression pages 13-13, dell’orco2019normalgcapspartly pages 1-2)

Zebrafish (Danio rerio)

Overexpression of human p.Arg120Leu reduced rod/cone markers, disrupted photoreceptors and RPE, and affected retinal/choriocapillaris-associated vasculature. Wild-type GUCA1A did not fully rescue the phenotype, supporting altered/gain-of-function behavior. p.Asp100Glu also injured photoreceptors and RPE, with a proposed dominant-negative mechanism. These are overexpression models and may not reproduce physiological heterozygous dosage. The corresponding human study was published in Genetics in Medicine in August 2017, DOI 10.1038/gim.2016.217, PMID 28125083. (chen2017guca1amutationcauses pages 7-8, georgiou2020retinalimagingin pages 13-15)

No disease-specific human iPSC, retinal-organoid, Drosophila, C. elegans, yeast or naturally affected animal model was established in the retrieved evidence.

Recent developments and evidence gaps

The most important recent advance is the 2025 largest-cohort study, which quantified onset, longitudinal acuity decline, symptom frequencies, bilateral symmetry, OCT sequence and preliminary genotype–phenotype associations. It was published February 19, 2025, DOI 10.1167/iovs.66.2.50. The strongest 2023 contribution retrieved was a review emphasizing that dominant retinal diseases often require silencing, editing or combined suppression/replacement rather than simple gene augmentation; no GUCA1A human program had entered clinical testing. (allon2025clinicalgeneticimaging pages 1-2, allon2025clinicalgeneticimaging pages 4-5)

Major unresolved fields are population prevalence/incidence, penetrance, founder effects, validated modifiers, gene–environment interaction, standardized quality-of-life outcomes, human retinal omics, biomarkers, prospective natural history and human therapeutic trials. The 2025 cohort’s modest size—19 patients and only one family for four of five alleles—means variant-specific prognostic estimates remain preliminary. (allon2025clinicalgeneticimaging pages 1-2, allon2025clinicalgeneticimaging pages 10-10)

Key primary references

1. Payne A, et al. Human Molecular Genetics. February 1998. “A mutation in guanylate cyclase activator 1A….” DOI: 10.1093/hmg/7.2.273. Foundational human Y99C pedigree. (payne1998amutationin pages 3-3)
2. Michaelides M, et al. Ophthalmology. August 2005;112:1442–1447. PMID 15953638. Human phenotype spectrum. (georgiou2020retinalimagingin pages 13-15)
3. Kitiratschky VBD, et al. Human Mutation. August 2009;30:E782–E796. DOI: 10.1002/humu.21055. Human variants plus biochemical functional testing. (kitiratschky2009mutationsinthe pages 1-3)
4. Jiang L, et al. PLoS ONE. March 5, 2013;8:e57676. DOI: 10.1371/journal.pone.0057676. L151F model and AAV-RNAi. (jiang2013rnaimediatedgenesuppression pages 13-13, jiang2013rnaimediatedgenesuppression pages 1-2)
5. Chen X, et al. Genetics in Medicine. August 2017;19:945–954. DOI: 10.1038/gim.2016.217; PMID 28125083. Human R120L family and zebrafish modeling. (chen2017guca1amutationcauses pages 7-8, georgiou2020retinalimagingin pages 13-15)
6. Marino V, et al. Human Molecular Genetics. December 2018;27. DOI: 10.1093/hmg/ddy311. Human E111V disease and biochemical mechanism. (marino2018anovelp.(glu111val) pages 2-3, marino2018anovelp.(glu111val) pages 8-9, marino2018anovelp.(glu111val) pages 3-3)
7. Dell’Orco D, Dal Cortivo G. Scientific Reports. December 2019;9:20105. DOI: 10.1038/s41598-019-56606-5. Wild-type GCAP compensation and species differences. (dell’orco2019normalgcapspartly pages 1-2)
8. Allon G, et al. Investigative Ophthalmology & Visual Science. February 19, 2025;66(2):50. DOI: 10.1167/iovs.66.2.50. Largest GUCA1A clinical cohort and natural-history analysis. (allon2025clinicalgeneticimaging pages 1-2, allon2025clinicalgeneticimaging pages 4-5)

References

1. (OpenTargets Search: GUCA1A-related retinopathy-GUCA1A): Open Targets Query (GUCA1A-related retinopathy-GUCA1A, 3 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

2. (allon2025clinicalgeneticimaging pages 1-2): Gilad Allon, Siying Lin, Anthony G. Robson, Gavin Arno, Magella M. Neveu, Pirro G. Hysi, Michel Michaelides, Andrew R. Webster, and Omar A. Mahroo. Clinical, genetic, imaging and electrophysiological findings in a cohort of patients with guca1a-associated retinopathy. Feb 2025. URL: https://doi.org/10.1167/iovs.66.2.50, doi:10.1167/iovs.66.2.50. This article has 3 citations and is from a domain leading peer-reviewed journal.

3. (allon2025clinicalgeneticimaging pages 4-5): Gilad Allon, Siying Lin, Anthony G. Robson, Gavin Arno, Magella M. Neveu, Pirro G. Hysi, Michel Michaelides, Andrew R. Webster, and Omar A. Mahroo. Clinical, genetic, imaging and electrophysiological findings in a cohort of patients with guca1a-associated retinopathy. Feb 2025. URL: https://doi.org/10.1167/iovs.66.2.50, doi:10.1167/iovs.66.2.50. This article has 3 citations and is from a domain leading peer-reviewed journal.

4. (marino2018anovelp.(glu111val) pages 3-3): Valerio Marino, Giuditta Dal Cortivo, Elisa Oppici, Paolo Enrico Maltese, Fabiana D’Esposito, Elena Manara, Lucia Ziccardi, Benedetto Falsini, Adriano Magli, Matteo Bertelli, and Daniele Dell’Orco. A novel p.(glu111val) missense mutation in guca1a associated with cone-rod dystrophy leads to impaired calcium sensing and perturbed second messenger homeostasis in photoreceptors. Sep 2018. URL: https://doi.org/10.1093/hmg/ddy311, doi:10.1093/hmg/ddy311. This article has 41 citations and is from a domain leading peer-reviewed journal.

5. (kitiratschky2009mutationsinthe pages 1-3): Veronique B.D. Kitiratschky, Petra Behnen, Ulrich Kellner, John R Heckenlively, Eberhart Zrenner, Herbert Jägle, Susanne Kohl, Bernd Wissinger, and Karl-Wilhelm Koch. Mutations in the guca1a gene involved in hereditary cone dystrophies impair calcium‐mediated regulation of guanylate cyclase. Human Mutation, 30:E782-E796, Aug 2009. URL: https://doi.org/10.1002/humu.21055, doi:10.1002/humu.21055. This article has 89 citations and is from a domain leading peer-reviewed journal.

6. (dell’orco2019normalgcapspartly pages 1-2): Daniele Dell’Orco and Giuditta Dal Cortivo. Normal gcaps partly compensate for altered cgmp signaling in retinal dystrophies associated with mutations in guca1a. Scientific Reports, Dec 2019. URL: https://doi.org/10.1038/s41598-019-56606-5, doi:10.1038/s41598-019-56606-5. This article has 24 citations and is from a peer-reviewed journal.

7. (jiang2013rnaimediatedgenesuppression pages 13-13): Li Jiang, Tansy Z. Li, Shannon E. Boye, William W. Hauswirth, Jeanne M. Frederick, and Wolfgang Baehr. Rnai-mediated gene suppression in a gcap1(l151f) cone-rod dystrophy mouse model. PLoS ONE, 8(3):e57676, Mar 2013. URL: https://doi.org/10.1371/journal.pone.0057676, doi:10.1371/journal.pone.0057676. This article has 19 citations and is from a peer-reviewed journal.

8. (marino2018anovelp.(glu111val) pages 1-1): Valerio Marino, Giuditta Dal Cortivo, Elisa Oppici, Paolo Enrico Maltese, Fabiana D’Esposito, Elena Manara, Lucia Ziccardi, Benedetto Falsini, Adriano Magli, Matteo Bertelli, and Daniele Dell’Orco. A novel p.(glu111val) missense mutation in guca1a associated with cone-rod dystrophy leads to impaired calcium sensing and perturbed second messenger homeostasis in photoreceptors. Sep 2018. URL: https://doi.org/10.1093/hmg/ddy311, doi:10.1093/hmg/ddy311. This article has 41 citations and is from a domain leading peer-reviewed journal.

9. (marino2018anovelp.(glu111val) pages 8-9): Valerio Marino, Giuditta Dal Cortivo, Elisa Oppici, Paolo Enrico Maltese, Fabiana D’Esposito, Elena Manara, Lucia Ziccardi, Benedetto Falsini, Adriano Magli, Matteo Bertelli, and Daniele Dell’Orco. A novel p.(glu111val) missense mutation in guca1a associated with cone-rod dystrophy leads to impaired calcium sensing and perturbed second messenger homeostasis in photoreceptors. Sep 2018. URL: https://doi.org/10.1093/hmg/ddy311, doi:10.1093/hmg/ddy311. This article has 41 citations and is from a domain leading peer-reviewed journal.

10. (allon2025clinicalgeneticimaging pages 5-10): Gilad Allon, Siying Lin, Anthony G. Robson, Gavin Arno, Magella M. Neveu, Pirro G. Hysi, Michel Michaelides, Andrew R. Webster, and Omar A. Mahroo. Clinical, genetic, imaging and electrophysiological findings in a cohort of patients with guca1a-associated retinopathy. Feb 2025. URL: https://doi.org/10.1167/iovs.66.2.50, doi:10.1167/iovs.66.2.50. This article has 3 citations and is from a domain leading peer-reviewed journal.

11. (marino2018anovelp.(glu111val) pages 2-3): Valerio Marino, Giuditta Dal Cortivo, Elisa Oppici, Paolo Enrico Maltese, Fabiana D’Esposito, Elena Manara, Lucia Ziccardi, Benedetto Falsini, Adriano Magli, Matteo Bertelli, and Daniele Dell’Orco. A novel p.(glu111val) missense mutation in guca1a associated with cone-rod dystrophy leads to impaired calcium sensing and perturbed second messenger homeostasis in photoreceptors. Sep 2018. URL: https://doi.org/10.1093/hmg/ddy311, doi:10.1093/hmg/ddy311. This article has 41 citations and is from a domain leading peer-reviewed journal.

12. (payne1998amutationin pages 3-3): A. Payne, S. Downes, D. Bessant, R. Taylor, G. Holder, M. Warren, A. C. Bird, and S. Bhattacharya. A mutation in guanylate cyclase activator 1a (guca1a) in an autosomal dominant cone dystrophy pedigree mapping to a new locus on chromosome 6p21.1. Human Molecular Genetics, 7(2):273-277, Feb 1998. URL: https://doi.org/10.1093/hmg/7.2.273, doi:10.1093/hmg/7.2.273. This article has 273 citations and is from a domain leading peer-reviewed journal.

13. (allon2025clinicalgeneticimaging pages 10-13): Gilad Allon, Siying Lin, Anthony G. Robson, Gavin Arno, Magella M. Neveu, Pirro G. Hysi, Michel Michaelides, Andrew R. Webster, and Omar A. Mahroo. Clinical, genetic, imaging and electrophysiological findings in a cohort of patients with guca1a-associated retinopathy. Feb 2025. URL: https://doi.org/10.1167/iovs.66.2.50, doi:10.1167/iovs.66.2.50. This article has 3 citations and is from a domain leading peer-reviewed journal.

14. (allon2025clinicalgeneticimaging pages 13-13): Gilad Allon, Siying Lin, Anthony G. Robson, Gavin Arno, Magella M. Neveu, Pirro G. Hysi, Michel Michaelides, Andrew R. Webster, and Omar A. Mahroo. Clinical, genetic, imaging and electrophysiological findings in a cohort of patients with guca1a-associated retinopathy. Feb 2025. URL: https://doi.org/10.1167/iovs.66.2.50, doi:10.1167/iovs.66.2.50. This article has 3 citations and is from a domain leading peer-reviewed journal.

15. (chen2017guca1amutationcauses pages 7-8): Xue Chen, X. Sheng, Wenjuan Zhuang, Xiantao Sun, Guohua Liu, Xun Shi, Guofu Huang, Yan-fang Mei, Yingjie Li, Xinyuan Pan, Ya-ni Liu, Zi-li Li, Qingshun Zhao, B. Yan, and Chen Zhao. Guca1a mutation causes maculopathy in a five-generation family with a wide spectrum of severity. Genetics in Medicine, 19:945-954, Aug 2017. URL: https://doi.org/10.1038/gim.2016.217, doi:10.1038/gim.2016.217. This article has 26 citations and is from a highest quality peer-reviewed journal.

16. (allon2025clinicalgeneticimaging pages 2-4): Gilad Allon, Siying Lin, Anthony G. Robson, Gavin Arno, Magella M. Neveu, Pirro G. Hysi, Michel Michaelides, Andrew R. Webster, and Omar A. Mahroo. Clinical, genetic, imaging and electrophysiological findings in a cohort of patients with guca1a-associated retinopathy. Feb 2025. URL: https://doi.org/10.1167/iovs.66.2.50, doi:10.1167/iovs.66.2.50. This article has 3 citations and is from a domain leading peer-reviewed journal.

17. (allon2025clinicalgeneticimaging pages 10-10): Gilad Allon, Siying Lin, Anthony G. Robson, Gavin Arno, Magella M. Neveu, Pirro G. Hysi, Michel Michaelides, Andrew R. Webster, and Omar A. Mahroo. Clinical, genetic, imaging and electrophysiological findings in a cohort of patients with guca1a-associated retinopathy. Feb 2025. URL: https://doi.org/10.1167/iovs.66.2.50, doi:10.1167/iovs.66.2.50. This article has 3 citations and is from a domain leading peer-reviewed journal.

18. (jiang2013rnaimediatedgenesuppression pages 1-2): Li Jiang, Tansy Z. Li, Shannon E. Boye, William W. Hauswirth, Jeanne M. Frederick, and Wolfgang Baehr. Rnai-mediated gene suppression in a gcap1(l151f) cone-rod dystrophy mouse model. PLoS ONE, 8(3):e57676, Mar 2013. URL: https://doi.org/10.1371/journal.pone.0057676, doi:10.1371/journal.pone.0057676. This article has 19 citations and is from a peer-reviewed journal.

19. (jiang2012rnainterferencegene pages 158-159): Li Jiang. Rna interference gene therapy for dominant photoreceptor degeneration disease in mouse models expressing mutant guanylate cyclase-activating protein 1. Text, Jan 2012. URL: https://doi.org/10.26053/0h-j46h-jcg0, doi:10.26053/0h-j46h-jcg0. This article has 0 citations and is from a peer-reviewed journal.

20. (avesani2026retinalnetworkdysfunction pages 12-14): Anna Avesani, Giuditta Dal Cortivo, Sabrina Asteriti, Giorgia Targa, Laura Veschetti, Valerio Marino, Amedeo Biasi, Carmen Longo, Barbara Cisterna, Karolina Saran, Giovanni Malerba, Andrzej T. Foik, Marco Cambiaghi, Lorenzo Cangiano, and Daniele Dell’Orco. Retinal network dysfunction precedes structural degeneration in severe guca1a cone-rod dystrophy. bioRxiv, Jul 2026. URL: https://doi.org/10.64898/2026.06.23.734025, doi:10.64898/2026.06.23.734025. This article has 1 citations.

21. (georgiou2020retinalimagingin pages 13-15): Michalis Georgiou, Kaoru Fujinami, and Michel Michaelides. Retinal imaging in inherited retinal diseases. Sep 2020. URL: https://doi.org/10.21037/aes-20-81, doi:10.21037/aes-20-81. This article has 53 citations.

22. (avesani2026retinalnetworkdysfunction pages 14-17): Anna Avesani, Giuditta Dal Cortivo, Sabrina Asteriti, Giorgia Targa, Laura Veschetti, Valerio Marino, Amedeo Biasi, Carmen Longo, Barbara Cisterna, Karolina Saran, Giovanni Malerba, Andrzej T. Foik, Marco Cambiaghi, Lorenzo Cangiano, and Daniele Dell’Orco. Retinal network dysfunction precedes structural degeneration in severe guca1a cone-rod dystrophy. bioRxiv, Jul 2026. URL: https://doi.org/10.64898/2026.06.23.734025, doi:10.64898/2026.06.23.734025. This article has 1 citations.

Artifacts

• Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• MONDO:0700376 (4 mentions) - the report calls it "if available", "GUCA1A-related retinopathy"; MONDO calls it GUCA1A-related retinopathy

Terms named inconsistently

The report gives these identifiers more than one name of its own:

• MONDO:0700376 - called "if available", "GUCA1A-related retinopathy"